Journals / Turkish Journal of Gastroenterology / 2022 / Cilt: 33 - Sayı: 7

Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?

Pages
587–595
Publication Date
2022-11-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Concomitant hepatic steatosis has no significant impact on the virological response in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The effect of hepatic steatosis on the response to antiviral therapy administered in chronic hepatitis B patients is yet to be clarified.
📊
Key Findings & Data:In this study, our aim was to determine the effect of hepatic steatosis on the virological response in chronic hepatitis B patients who were treated with entecavir or tenofovir disoproxil fumarate.
💡
Conclusion & Impact:Conclusion: Concomitant hepatic steatosis has no significant impact on the virological response in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment.
🔬Design:Modeling & Simulation
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: The effect of hepatic steatosis on the response to antiviral therapy administered in chronic hepatitis B patients is yet to be clarified. In this study, our aim was to determine the effect of hepatic steatosis on the virological response in chronic hepatitis B patients who were treated with entecavir or tenofovir disoproxil fumarate. Methods: This retrospective cohort study was performed using the data of liver biopsy-proven chronic hepatitis B patients with or without hepatic steatosis, who received entecavir or tenofovir disoproxil fumarate treatment between 2012 and 2017. The undetectable serum hepatitis B virus deoxyribonucleic acid level under treatment was defined as the complete virological response. The predictors of virological response were determined, and it was checked whether the virological response was affected by hepatic steatosis in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment. Results: A total of 324 chronic hepatitis B patients, of which 203 (63%) were males, were included in the study. The median age of the patients was 42years (range: 35-51 years). Hepatic steatosis was observed in 25% of the patients, and steatohepatitis in 4%. The median time to complete virological response was found to be 6 months (range: 3-9 months). In the full analysis model, the log hepatitis B virus deoxyribonucleic acid was determined as the factor most associated with virological response (P < .001). No statistically signifi cant relationship was detected between hepatic steatosis and virological response (P = .409). Conclusion: Concomitant hepatic steatosis has no significant impact on the virological response in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment.

🔖

Cite This Article

ATALAY, R., SAYAR, S., AYRANCI, F. G., ÇAKMAK, Ş., TANBOĞA, İ. H., DOĞANAY, L., ÖZDİL, K. (2022). Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?. Turkish Journal of Gastroenterology, Cilt: 33 - Sayı: 7, 587–595. https://ajindex.com/articles/606185

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta analytic assessment of prevalence, incidence, and outcomes. Hepa tology. 2016
  2. 64(1):73-84. [CrossRef] 2. Zhu Y, Yang Q, Lv F, Yu Y. The effect of hepatosteatosis on response to antiviral treatment in patients with chronic hepatitis B: a meta analysis. Gastroenterol Res Pract. 2017
  3. 1096406. [CrossRef] 3. Aller R, Fernández-Rodríguez C, Lo Iacono O, et al. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD): Clinical practice guideline. Gastroenterol Hepatol. 2018
  4. 41(5):328- 349. [CrossRef] 4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and man agement of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatol ogy. 2018
  5. 67(1):328-357. [CrossRef] 5. European Association for the Study of the Liver. EASL 2017 clini cal practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017
  6. 67(2):370-398. [CrossRef] 6. Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014
  7. 59(10):2571- 2579. [CrossRef] 7. Torres DM, Harrison SA. Nonalcoholic fatty liver disease. In: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 11th ed. Amsterdam: Elsevier
  8. e4. 8. Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol. 2005
  9. 43(1):38-44. [CrossRef] 9. Shi JP, Fan JG, Wu R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008
  10. 23(9):1419-1425. [CrossRef] 10. Rastogi A, Sakhuja P, Kumar A, et al. Steatosis in chronic hepa titis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol. 2011
  11. 54(3):454- 459. [CrossRef] 11. Fan JG, Chitturi S. Hepatitis B and fatty liver: causal or coinci dental? J Gastroenterol Hepatol. 2008
  12. 23(5):679-681. [CrossRef] 12. Wong VW-S, Wong GL-H, Chu WC-W, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012
  13. 56(3):533-540. [CrossRef] 13. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected pati